secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001140361-24-000836
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed reports prelim 2023 ARIKAYCE sales of ~$305.2M; guides 2024 to $340-360M
-------------------------------------------------------------------------------

- ARIKAYCE 2023 global net sales ~$305.2M, exceeding upper end of guidance, 24% YoY growth.
- 2024 ARIKAYCE revenue guidance $340-360M (midpoint 15% growth).
- Phase 3 ASPEN (brensocatib) topline data expected latter part of Q2 2024; potential U.S. launch mid-2025.
- TPIP Phase 2 PH-ILD study enrollment completed (39 patients); topline data expected Q2 2024.
- Phase 3 ENCORE (ARIKAYCE label expansion) topline readout expected 2025; FDA feedback received on ARISE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124000836/0001140361-24-000836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036124000836/ef20017898_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-000836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer